The Role of Cisplatin Loaded Biocompatible Nanoparticles in Cancer Treatment
Abstract
Chemotherapeutic treatments focusing on cisplatin, ovarian cancer, testicular cancer, breast cancer, colon cancer, lung cancer etc. seen in adults and children. Cisplatin is an antineoplastic agent frequently used in cancer types. Drug resistance to cisplatin has an effect on the success of the treatment. After cisplatin-administered treatments, patients may experience cisplatin-induced side effects of various toxic dimensions, such as nausea, nephrotoxicity, cardiotoxicity, hepatotoxicity, and neurotoxicity. As a result of the literature review, various studies have been carried out to reduce the side effects and toxic effects of cisplatin and other anticancer molecules without interfering with their activities. In this study, we planned to prepare a cisplatin-loaded chitosan nanoparticle formulation based on the ionic gelation method using chitosan and tripolyphosphate (TPP) with the information obtained from the literature. In this study, chitosan nanoparticles containing the same concentration of cisplatin were applied to MDA-MB-231 breast cancer cell lines obtained from the American Type Culture Collection (ATCC). As a result, biocompatible nanoparticles with similar cytotoxic effects cause less side effects in other cells and tissues than other nanoparticles.
Keywords
Cancer, Cisplatin, Chitosan, Nanoparticle, Cytotoxicity.
Supporting Institution
TÜBİTAK
Project Number
1919B012002787
Thanks
I would like to state that I received support from the TUBITAK 2209 project numbered 1919B012002787 in this study. In addition, this study was performed at Cumhuriyet University Faculty of Pharmacy, Pharmaceutical Biotechnology Laboratory and Cumhuriyet University Faculty of Medicine Cancer Research Center.
References
- [1] Zhang B., Pan X., Cobb GP., Anderson TA., MicroRNAs as Oncogenes and Tumor Suppressors, Dev Biol., 302(1) (2007) 1-12.
- [2] Hanahan D., Weinberg R.A., Hallmarks of Cancer: the Next Generation, Cell, 144 (2011) 646-74.
- [3] American Cancer Society, Cancer Facts & Figures, Atlanta: American Cancer Society, 2012. Available at https://www.cancer.org/research/cancer-facts-statistic.
- [4] Lind M.J., Principles of Cytotoxic Chemotherapy, Medicine, 36(1) (2008) 19–23.
- [5] Eastman A., Improving Anticancer Drug Development Begins with Cell Culture: Misinformation Perpetrated by the Misuse of Cytotoxicity Assays, Oncotarget, 8 (2017) 8854–8866.
- [6] Donna S.S., Robert D.K., Introduction to Cancer Chemotherapeutics, Chem. Rev., 109(7) (2009) 2859–2861.
- [7] Rosenberg B., Archie W.P., Stanley T., Stephen K.C., Cisplatin: Its History and Possible Mechanisms of action, Academic Press, (1980) 9–12.
- [8] Dasari S., Tchounwou P.B., Cisplatin in Cancer Therapy: Molecular Mechanisms of action, European Journal of Pharmacology, 740(3) (2014) 64-378.
- [9] Browning R.J., Reardon P.J.T., Parhizkar M., Pedley R.B., Edirisinghe M., Knowles J.C., Stride E., Drug Delivery Strategies for Platinum-Based Chemotherapy, ACS Nano., 11(9) (2017) 8560-8578.
- [10] Tsimberidou A.M., Braiteh F., Stewart D.J., Kurzrock R., Ultimate Fate of Oncology Drugs Approved by the Us Food And Drug Administration without a Randomized Trial, Journal of Clinical Oncology, 27(36) (2009) 6243-6250.